CVR 87339815Public limited company (A/S)Fremstilling af parfume, hårshampoo, tandpasta mv. (204200)GræstedFounded 11 Apr 1984
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about PHARMA-TRADE A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
3
CVR, 2019
Revenue
325.1M
DKK, annual report 2025
-14.9% on 2024
Result
+21.2M
DKK, annual report 2025
Equity
254M
DKK, annual report 2025
PIF Holding ApSCVR 29605351, 50% to under 66.7% of capital and votes, since 30 Jun 2009
DANYL FINANS A/SCVR 29605378, 50% to under 66.7% of capital and votes, since 30 Jun 2009
Operating company
Dandex estimate: revenue or gross profit in the 2025 reportHenrik Overgaardsince 21 Apr 1999
CVR 2960535150% to under 66.7% of capital and votessince 30 Jun 2009
CVR 2960537850% to under 66.7% of capital and votessince 30 Jun 2009
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
1 Danish company, which own 1 more one level down.
SubsidiaryCVR 56000828100% of capital and votes
SubsidiaryCVR 35225528100% of capital and votes
Found by searching the CVR owner register (ejerregister) for PHARMA-TRADE A/S as owner: Danish companies it holds 5% or more of, and their holdings one level down. Foreign holdings are not in CVR.
CVR 35225528100% of capital and votes29 Dec 2017 to 19 May 2020
CVR 70721910100% of capital and votes30 Jun 2009 to 1 May 2019
CVR 12071787100% of capital and votes1 Jan 2010 to 1 May 2019
CVR 54556314100% of capital and votes1 Mar 2003 to 29 Dec 2017
Decided by Dandex with fixed rules from CVR and the filed annual reports, and for the auditor's report, the business model and the revenue model a calibrated decision model reading the report's text and the purpose clause, not registered by the company. Each label links to its definition.
11 Apr 1984 to 16 Nov 2026.
11 Apr 1984 to 16 Nov 2026.
Dec 2019, monthly: 3 employees, 3 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | Q1 2010 | Q2 2010 | Q3 2010 | 2011 | 2012 | 2013 | 2014 | Jan 2015 | Feb 2015 | Mar 2015 | Apr 2015 | May 2015 | Jun 2015 | Jul 2015 | Aug 2015 | Sep 2015 | Oct 2015 | Nov 2015 | Dec 2015 | Jan 2016 | Feb 2016 | Mar 2016 | Apr 2016 | May 2016 | Jun 2016 | Jul 2016 | Aug 2016 | Sep 2016 | Oct 2016 | Nov 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Sep 2017 | Oct 2017 | Nov 2017 | Dec 2017 | Jan 2018 | Feb 2018 | Mar 2018 | Apr 2018 | May 2018 | Jun 2018 | Jul 2018 | Aug 2018 | Sep 2018 | Oct 2018 | Nov 2018 | Dec 2018 | Jan 2019 | Feb 2019 | Mar 2019 | Apr 2019 | May 2019 | Jun 2019 | Jul 2019 | Aug 2019 | Sep 2019 | Oct 2019 | Nov 2019 | Dec 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | No count | No count | No count | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 |
| FTE | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 |
| Series | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Quarterly | Quarterly | Quarterly | Annual | Annual | Annual | Annual | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's own headcount as CVR records it, not the annual report's average, which may cover a group. Annual 1997 to 2009 and 2011 to 2014; quarterly Q1 2010 to Q3 2010; monthly Jan 2015 to Dec 2019.
CVR changed its monthly method in Oct 2019, so a step at that month need not be real.
Latest Dec 2019, published 9 Mar 2022. Source: CVR employment series (Årsbeskæftigelse, Kvartalsbeskæftigelse, Månedsbeskæftigelse).
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 366,150 | 337,738 | 374,750 | 382,244 | 325,128 |
| Operating profit | +59,517 | +36,671 | +44,689 | +55,383 | +27,603 |
| Result for the year | +46,441 | +28,015 | +34,354 | +43,142 | +21,231 |
| Equity | 242,438 | 238,089 | 251,385 | 272,786 | 254,017 |
| Total assets | 341,730 | 324,429 | 337,161 | 350,285 | 326,834 |
| Employees (average) | 196 | 181 | 177 | 180 | 173 |
| Credit metrics (Dandex calculations) | |||||
| Revenue growth (omsætningsvækst) | 9.4% | -7.8% | 11% | 2% | -14.9% |
| EBIT margin (overskudsgrad) | 16.3% | 10.9% | 11.9% | 14.5% | 8.5% |
| EBITDA | 71,945 | 49,264 | 57,058 | 67,293 | 40,088 |
| EBITDA margin (EBITDA-margin) | 19.7% | 14.6% | 15.2% | 17.6% | 12.3% |
| Employee growth (vækst i antal ansatte) | 7.1% | -7.6% | -2.2% | 1.7% | -3.9% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex (investeringer i anlægsaktiver) | 9,973 | 8,759 | 6,926 | 8,686 | 17,063 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages. Gearing and interest coverage are multiples. Rows marked Pro hold a value in the Pro plan. Definitions. Group figures (koncern).
Annual report 2025
1 Jan 2025 to 31 Dec 2025, published 21 May 2026
Annual report 2024
1 Jan 2024 to 31 Dec 2024, published 26 May 2025
Annual report 2023
1 Jan 2023 to 31 Dec 2023, published 17 Jun 2024
Annual report 2022
1 Jan 2022 to 31 Dec 2022, published 31 May 2023
Annual report 2021
1 Jan 2021 to 31 Dec 2021, published 2 May 2022
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
The rows marked Pro on this page hold values in the Pro plan. For PHARMA-TRADE A/S, that is:
Have Pro? Sign in to see the values on this page.
Each registered value from the day it took effect, newest first.
Merger (fusion), as the continuing company (fortsættende selskab)
From CVR, read 16 Nov 2026. Text such as the signing rule and purpose is shown as registered.
From CVR, read 16 Nov 2026. A change is counted each time the registry records a new value, so a corrected address or an audit firm under a new entity counts too.
16 registrations, newest first. As published by Erhvervsstyrelsen, in Danish, with people's street addresses cut to postcode and city.
Bestyrelse:
Fratrådte:
Niels Ebbe Valdal, den 18.11.2024.
Tiltrådte:
Kresten Mikael Valdal, den 18.11.2024.
Bestyrelse:
Fratrådte:
Ib Preben Overgaard, (formand), den 11.06.2024, Jan Overgaard, den 11.06.2024.
Tiltrådte:
Jan Overgaard, (formand), den 11.06.2024.
Vedtægter ændret:
14.01.2011.
Nyt binavn: PERPHARMA A/S (PHARMA-TRADE A/S).
Selskabet tegnes af en direktør alene eller af to bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.
Selskabet er fusioneret med CVR-NR. 16985171 PERPHARMA A/S, der samtidig er opløst.
Erhvervs- og Selskabsstyrelsen har modtaget
fusionsplan for fusion mellem
CVR-NR. 87339815 PHARMA-TRADE A/S (fortsættende). der tillige driver virksomhed under navnet FATIMA A/S (PHARMA-TRADE A/S).
CVR-NR. 16985171 PERPHARMA A/S (ophørende).
Endvidere er modtaget erklæring fra
vurderingsmændene om kreditorernes stilling.
Ved kommunalreformen den 1. januar 2007 er hjemstedskommunen ændret.
Vedtægter ændret:
19.05.2005.
Nyt navn:
PHARMA-TRADE A/S.
Binavn:
FATIMA A/S (PHARMA-TRADE A/S).
Vedtægter ændret:
28.04.2003.
Nyt navn:
PHARMATRADE A/S.
Nyt binavn: FATIMA A/S (PHARMATRADE A/S).
Vedtægter ændret:
19.04.2000.
Kapitalforhøjelse:
kr. 1.000.000,00 indbetalt ved overførte reserver / overskud, kurs 100,00.
Kapitalen udgør herefter kr. 3.000.000,00.
Bestyrelse:
Tiltrådt som formand:
Ib Preben Overgaard, den 21.04.1999.
Direktion:
Udtrådt af direktionen:
Ib Preben Overgaard, den 21.04.1999, den 21.04.1999.
Indtrådt i direktionen:
Fabrikant Henrik Overgaard, den 21.04.1999.
Revision:
Indtrådt i revisionen:
KRESTEN FOGED STATSAUTORISERET REVISIONSAKTIESELSKAB, Frederiksgade 1, 1265 København K.
Revision:
Udtrådt af revisionen:
Revisionsaktieselskabet Kresten Foged.
Vedtægter ændret:
15.10.1996.
Ny adresse:
Skaaremosevej 11-14, Blistrup, 3230 Græsted.
Ny kommune:
Græsted-Gilleleje.
Vedtægter ændret:
09.08.1994.
Kapitalforhøjelse:
kr. 1.700.000,00 indbetalt ved overførte reserver / overskud, kurs 100,00.
Kapitalen udgør herefter kr. 2.000.000,00.
Vedtægter ændret:
10.11.1988
Ny adresse:
Hvedemarken 16, 3520 Farum
Ny kommune:
Farum
REG.NR. A/S67339
NAVN: FATIMA A/S
ADRESSE: Henrik Hertz vej 4, 2920 Charlottenl
Stiftelsesdato:
11.04.1984
Kapital:
kr. 300.000,00
Indbetalingsmåde:
kontant/i værdier kr. 300.000,00 til kurs 100,0
Bestyrelse:
Fabrikant Ib Preben Overgaard, Disponent Jan Overgaard, Disponent Henrik Overgaard, Advokat Niels Ebbe Valdal
Direktion:
Fabrikant Ib Preben Overgaard
Selskabet tegnes af to medlemmer af
bestyrelsen i forening eller af en direktør
alene eller af den samlede bestyrelse
Revision:
REVISIONSAKTIESELSKABET KRESTEN FOGED, 1265 København K
Første regnskabsår:
00.00 - 00.00
Regnskabsår:
01.01 - 31.12
1 registered in CVR.
P-number 1002769245Skaaremosevej 11, 3230 Græsted